You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Immune mobilizing monoclonal T cell receptor against cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Synovial Sarcoma Trial in Houston (Fludarabine phosphate, NY-ESO-1 TCR/IL-15 NK, Cyclophosphamide)

Not yet recruiting
  • Synovial Sarcoma
  • Fludarabine phosphate
  • +2 more
  • Houston, Texas
    MD Anderson Cancer Center
Oct 9, 2023

Chronic GVHD, Hematologic and Lymphocytic Disorder, Steroid Refractory GVHD Trial in Duarte (procedure, biological, other)

Not yet recruiting
  • Chronic Graft Versus Host Disease
  • +2 more
  • Biopsy
  • +11 more
  • Duarte, California
    City of Hope Medical Center
Aug 7, 2023

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Atlanta (Tocilizumab, Venetoclax)

Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Atlanta, Georgia
    Emory University Hospital/Winship Cancer Institute
Jan 24, 2023

Recurrent Adult T-Cell Leukemia/Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Adult T-Cell

Recruiting
  • Recurrent Adult T-Cell Leukemia/Lymphoma
  • +3 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Nov 18, 2022

Folliculotropic Mycosis Fungoides, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Sezary Syndrome Trial in Duarte (procedure,

Active, not recruiting
  • Folliculotropic Mycosis Fungoides
  • +7 more
  • Extracorporeal Photopheresis
  • +3 more
  • Duarte, California
    City of Hope Medical Center
Dec 8, 2022

Platinum-Resistant Ovarian Carcinoma Trial in Duarte (Chimeric Antigen Receptor T-cells, Cyclophosphamide, Fludarabine)

Recruiting
  • Platinum-Resistant Ovarian Carcinoma
  • Chimeric Antigen Receptor T-cells
  • +2 more
  • Duarte, California
    City of Hope Medical Center
Jul 21, 2022

Multiple Myeloma, Smoldering Multiple Myeloma Trial in Boston (Ciltacabtagene Autoleucel, Cyclophosphamide, Fludarabine

Not yet recruiting
  • Multiple Myeloma
  • Smoldering Multiple Myeloma
  • Ciltacabtagene Autoleucel
  • +2 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Mar 2, 2023

HLA Typing and Tumor Neoantigen Identification forPhase I/II

Recruiting
  • Ovarian Cancer
  • +5 more
    • Houston, Texas
      MD Anderson Cancer Center
    Jul 27, 2022

    Recurrent DLBCL, Refractory DLBCL Trial in Sacramento (Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine

    Recruiting
    • Recurrent Diffuse Large B-Cell Lymphoma
    • Refractory Diffuse Large B-Cell Lymphoma
    • Chimeric Antigen Receptor T-Cell Therapy
    • +3 more
    • Sacramento, California
      University of California Davis Comprehensive Cancer Center
    Mar 8, 2022

    DLBCL, Not Otherwise Specified, Recurrent DLBCL, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma Trial in Seattle

    Terminated
    Has Results
    • Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
    • +5 more
    • Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014
    • +3 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Aug 1, 2022

    Select Advanced Solid Tumors Trial in United Kingdom, United States (IMC-F106C, anti-PD(L)1)

    Recruiting
    • Select Advanced Solid Tumors
    • Los Angeles, California
    • +12 more
    Mar 10, 2022

    Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Duarte (Acalabrutinib,

    Recruiting
    • Recurrent Mantle Cell Lymphoma
    • Refractory Mantle Cell Lymphoma
    • Acalabrutinib
    • CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
    • Duarte, California
      City of Hope Comprehensive Cancer Center
    Jun 16, 2022

    Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer Trial in United States

    Recruiting
    • Non Small Cell Lung Cancer
    • +11 more
    • Denver, Colorado
    • +3 more
    Jan 10, 2023

    Sarcoma, HER-2 Protein Overexpression Trial in Houston (cells, Pembrolizumab Injectable Product, Nivolumab Injectable Product)

    Recruiting
    • Sarcoma
    • HER-2 Protein Overexpression
    • cells
    • +3 more
    • Houston, Texas
      Texas Children's Hospital
    Dec 8, 2021

    Mycosis Fungoides, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Sezary Syndrome Trial in Atlanta (procedure, biological,

    Recruiting
    • Mycosis Fungoides
    • +2 more
    • Extracorporeal Photopheresis
    • +2 more
    • Atlanta, Georgia
      Emory University Hospital
    Jun 15, 2022

    Advanced Melanoma Trial (Tebentafusp, Tebentafusp with Pembrolizumab, Investigators Choice)

    Not yet recruiting
    • Advanced Melanoma
    • (no location specified)
    Sep 19, 2022

    Mycosis Fungoides, Recurrent Mycosis Fungoides, Recurrent Mycosis Fungoides and Sezary Syndrome Trial in United States

    Recruiting
    • Mycosis Fungoides
    • +11 more
    • Biospecimen Collection
    • +5 more
    • Duarte, California
    • +12 more
    Jan 7, 2023

    Multiple Myeloma Trial in Japan, United States (JNJ-68284528)

    Completed
    • Multiple Myeloma
    • JNJ-68284528
    • Phoenix, Arizona
    • +20 more
    Oct 5, 2022

    Non-Malignant Tumor Trial in Seattle (biological, drug, radiation, procedure)

    Recruiting
    • Non-Malignant Neoplasm
    • Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10
    • +7 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Aug 29, 2022

    Recurrent Anaplastic Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma Trial in

    Recruiting
    • Recurrent Anaplastic Large Cell Lymphoma
    • +9 more
    • Anti-CD30/CD16A Monoclonal Antibody AFM13
    • +4 more
    • Houston, Texas
      M D Anderson Cancer Center
    Aug 9, 2022

    Recurrent Neuroblastoma, Recurrent Osteosarcoma, Refractory Neuroblastoma Trial in Bethesda, Seattle, Madison (Cyclophosphamide,

    Recruiting
    • Recurrent Neuroblastoma
    • +3 more
    • Palo Alto, California
    • +3 more
    Jan 25, 2023

    Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Bladder Carcinoma

    Recruiting
    • Clinical Stage III Cutaneous Melanoma AJCC v8
    • +41 more
    • Ipilimumab
    • +2 more
    • Houston, Texas
      M D Anderson Cancer Center
    Oct 11, 2022

    Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8 Trial in United States

    Recruiting
    • Metastatic Renal Cell Carcinoma
    • +3 more
    • Avelumab
    • +7 more
    • Danville, Illinois
    • +4 more
    Jul 29, 2022

    Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous

    Active, not recruiting
    • Clinical Stage III Cutaneous Melanoma AJCC v8
    • +20 more
    • Ipilimumab
    • +3 more
    • Tampa, Florida
    • +6 more
    Jan 13, 2023

    Uveal Melanoma Trial (Tebentafusp)

    Available
    • Uveal Melanoma
    • (no location specified)
    Jan 5, 2022